RxDoctor Payments Data

Louis Galdieri, MD

Urology · West Orange, NJNPI 1124024146

Payments from drug & device makers

$1,840in general payments, 2019–2025

Across 120 payments — averaging $15.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$205
  • Pfizer$181
  • Johnson & Johnson$144
  • Bayer$116
  • Acerus Pharmaceuticals Corporation$84
  • Coloplast$80
  • plus $1K from 29 others

What the payments were for

  • Food & beverage$1,77997%
  • Education$613%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Astellas Pharma US Inc14$205
Pfizer13$181
Johnson & Johnson7$144
Bayer7$116
Acerus Pharmaceuticals Corporation6$84
Coloplast6$80
Merck5$74
Medtronic3$70
Amgen5$69
Tolmar Pharmaceuticals, Inc.5$66
Myovant Sciences Inc.5$66
AstraZeneca4$59
AbbVie(2 entities)4$58
Boston Scientific4$54
Hollister Incorporated2$48
Antares Pharma, Inc.3$45
180 Medical, Inc.2$42
Myriad Genetic Laboratories, Inc.2$39
Urovant Sciences Inc2$34
ABC Home Medical Supply, Inc.1$34
Clarus Therapeutics Inc.2$30
Ferring Pharmaceuticals Inc.2$28
Blue Earth Diagnostics2$26
Olympus America Inc.1$25
Dentsply IH Inc.1$19
C. R. Bard, Inc. & Subsidiaries1$18
Verity Pharmaceuticals Inc.1$18
Rochester Medical Corporation1$18
Mission Pharmacal Company1$17
Metuchen Pharmaceuticals1$17
Foundation Medicine, Inc.1$15
Avadel Specialty Pharmaceuticals, LLC1$14
Dendreon Pharmaceuticals LLC1$14
Aytu Biopharma, Inc.1$12
Innovative Medical Technologies, LLC3$0

How this compares

$1,840 in reported general payments places this provider in the 40th percentile of 401 urology providers in New Jersey.

See all urology providers in New Jersey

Medicare billing

Part B allowed, 2024
$58,758
Medicare patients
211
Services billed
1,606

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron43$34,657
GemtesaVibegron22$11,531
Alfuzosin Hcl ErAlfuzosin Hcl228$6,472
Potassium Citrate ErPotassium Citrate50$6,306
Tamsulosin Hcl215$4,849
Finasteride177$3,734
Dutasteride55$2,269
Silodosin29$1,810
Trimethoprim12$403
Oxybutynin Chloride16$398
Allopurinol21$307
Cephalexin23$128

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$205$34,65743 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 401 urology providers in New Jersey.

Other urology in West Orange

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →